The pharmacology of calcium channel antagonists: a novel class of anti-migraine agents?
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009539:Nicotinic Acids / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D009553:Nimodipine; D014666:Vasomotor System / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D009539:Nicotinic Acids; D003533:Cyproheptadine; D009553:Nimodipine; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine